Anmarks Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 14-12-2024
- Paid Up Capital ₹ 2.50 M
as on 14-12-2024
- Company Age 29 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.49 Cr
as on 14-12-2024
- Revenue %
(FY 2020)
- Profit -111.62%
(FY 2020)
- Ebitda 85.24%
(FY 2020)
- Net Worth -5.92%
(FY 2020)
- Total Assets -10.95%
(FY 2020)
About Anmarks Pharmaceuticals
The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M.
The company currently has active open charges totaling ₹1.49 Cr.
Ashok Agarwal, Rajesh Jain, Rajesh Gaba, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231RJ1995PTC009699
- Company No.
009699
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
16 Mar 1995
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Jaipur
Industry
Company Details
- Location
Ajmer, Rajasthan, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Anmarks Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashok Agarwal  | Director | 16-Mar-1995 | Current |
| Rajesh Jain | Director | 16-Mar-1995 | Current |
| Rajesh Gaba | Director | 16-Mar-1995 | Current |
| Madhu Narang | Director | 16-Mar-1995 | Current |
Financial Performance of Anmarks Pharmaceuticals.
Anmarks Pharmaceuticals Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 111.62% decrease in profit. The company's net worth dipped by a decrease of 5.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anmarks Pharmaceuticals?
In 2019, Anmarks Pharmaceuticals had a promoter holding of 98.40% and a public holding of 1.60%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 20 Jan 2012 | ₹1.00 M | Open |
Bank Of Baroda Creation Date: 20 Jan 2012 | ₹1.00 M | Open |
Bank Of Baroda Creation Date: 05 Feb 2007 | ₹1.29 Cr | Open |
How Many Employees Work at Anmarks Pharmaceuticals?
Unlock and access historical data on people associated with Anmarks Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anmarks Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anmarks Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
